How does gait differ in children with achondroplasia?
2021-03-12Research
What is still to be understood on how gait in children with achondroplasia is altered compared to average height children.
What is still to be known about achondroplasia
2021-03-12Research
A recently published article by Julie Hoover-Fong et al.1 seeks to synthesize the current knowledge base about the nature, incidence, chronology, and the interrelationships of achondroplasia-related comorbidities across the lifespan.
New potential treatment for achondroplasia by the Tsumaki lab & Astellas Pharma Inc.
2020-12-27Research
The Tsumaki lab, at the Center for iPS Cell Research and Application (CiRA), Kyoto University, is leading new research for achondroplasia with ASP5878, an FGFR inhibitor, using iPS cells. This is a study in collaboration with Astellas Pharma.
Future Perspectives on the Treatment of Achondroplasia
2020-12-22Research
Among many rare skeletal disorders, achondroplasia is one of the best known and understood. Yet, its management and treatment are still a major challenge for research centers.
First children with achondroplasia receive Recifercept
2020-12-16Research
Pfizer released a Press Statement of the first children with achondroplasia receiving Recifercept, initiating the Phase 2 clinical trial
Phase 2 Clinical trial with Recifercept starts in December 2020
2020-11-24Research
The Phase 2 Study Of Safety, Tolerability And Effectiveness Of Reciferecept In Children With Achondroplasia is now live in Clinicaltrial.gov
